公开(公告)号：US20240029819A1

公开(公告)日：2024-01-25

申请号：US18140095

申请日：2023-04-27

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yifat MERBL ,  Assaf KACEN ,  Yishai LEVIN ,  David MORGENSTERN

IPC: G16B15/20 ,  G16B15/30 ,  G16B40/20

CPC classification number: G16B15/20 ,  G16B15/30 ,  G16B40/20

Abstract: Agents binding modified antigen dependent peptides and use of same are provided. Accordingly, there is provided an agent capable of specifically binding an MHC presented peptide comprising a post translational modification (PTM), wherein the agent does not bind a peptide having the same amino acid sequence as said peptide but does not comprise said modification. Also provided are polynucleotides encoding the agent, cells expressing same and methods of use thereof. Also provided is a computer implemented method for generating a dataset of PTM on MHC bound peptides.

公开(公告)号：US20220155305A1

公开(公告)日：2022-05-19

申请号：US17586870

申请日：2022-01-28

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yifat MERBL ,  Aaron JAVITT ,  Assaf KACEN ,  Avital EISENBERG-LERNER ,  Merav SHMUELI

IPC: G01N33/574 ,  A61K39/395

Abstract: A method of treating lung cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent that downregulates an amount or activity of a polypeptide selected from the group consisting of CASC5, MYOF, CTNS, FCGR2B, PCDHGC5, POMGNT2, ACSL1, CTAGE5, TECPR2, WDR48, MCPH1, PPP2R3C, ADRB1, JAG2, GEMIN7, PTPRB, PRMT9, PSME4, Ube2L3, TP53RK and PSME3.